CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Mark G. Woodcock, Haniel A. Araújo et al.|Nature|2024Cited by 171
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Gary D. Steinberg, Edward Uchio et al.|Nature Medicine|2024Cited by 64
MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLCFerdinandos Skoulidis, Jack A. Roth, Kathryn C. Arbour et al.|Journal of Thoracic Oncology|2019Cited by 3